PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for cardiovascular diseases. Its lead product candidate is bentracimab, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III clinical trials. The company is also developing treatments for pulmonary arterial hypertension and resistant hypertension. It has a co-development agreement with SFJ Pharmaceuticals X, Ltd. The company filed for Chapter 11 bankruptcy in October 2022.